Promising drug to treat Covid-19



[ad_1]

Remdesivir Therapy: One can be cautiously optimistic. (Icon Image)

Image: iStock

The first experiences with the remdesivir agent originally developed for Ebola give us confidence. Reliable results from large international studies are still pending.

Remdesivir has been a promising candidate for Covid-19 treatment for several weeks. In a study by the University of Chicago Clinic, the drug, originally developed against Ebola, led to a rapid reduction in fever and a reduction in symptoms of lung disease.

After less than a week of drug therapy, nearly all patients were discharged, according to a report released Thursday afternoon by online medical news platform “Stat.” The company’s shares rose 16 percent after the US market closed.

Posted without permission

The drug’s maker, Gilead, said the data had to be analyzed to draw conclusions. The university clinic in Chicago indicated in an email that partial data from an ongoing study should not be used to obtain results. The contents of an internal forum for scientists were recorded and published without permission.

Kathleen Mullane, an infectious disease expert at the University of Chicago, made it clear to “Stat” that she shouldn’t read the information too much.

The pharmaceutical company expects to be able to announce the first results of the ongoing phase 3 study by the end of the month. Chicago University Hospital is one of 152 hospitals participating in the Gilead study of severely ill Covid 19 patients.

According to the “Stat” news platform, 125 people were treated in Chicago as part of the study. Of the patients included in the analysis, 113 had a severe course of the disease. They treated you with daily infusions of Remdesivir.

According to pharmaceutical manufacturer Gilead, the drug is currently being tested in six studies worldwide, including in Switzerland, for the treatment of patients with Covid 19.

Study with individual healing attempts.

If approved therapies are not available for a patient, physicians may use an active ingredient without authorization under certain conditions (compassionate use). In an April 10 publication in the “New England Journal of Medicine,” such individual healing attempts with remdesivir were reported, which were carried out with a small group of patients at Cedars-Sinai Medical Center in Los Angeles, USA. ).



Of the 53, mostly male patients, 34 had to be mechanically ventilated. A third of the test subjects had already reached the age of 70. 36 of the treated patients showed an improvement on average 18 days after the first infusion with Remdesivir. Eight patients worsened their health. Seven of them died.

These data should also be used with caution. Only a small group of patients was observed. Furthermore, there was no control group of study participants for comparison who were not treated with remdesivir, but only with standard therapy.

Whether or not Remdesivir receives approval for Covid-19 treatment depends on the results of ongoing clinical trials.

The coronavirus crisis: a timeline

Back to the home page

[ad_2]